NARANHAY
Advanced Antimicrobial Biotechnology
Company Overview
Snapshot
Founded in January 2020 by Dr. Aaron Mazin, Maxim Mikhaylov, Adv. Simeon Saharov, and Dr. Yehoshua Maor, NARANHAY operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing proprietary antimicrobial solutions.
Business overview
NARANHAY is an advanced antimicrobial biotechnology company specializing in proprietary, localized formulations designed to target pathogenic biofilms and microbial drivers of chronic inflammation. Its platform utilizes a mechanism-focused R&D approach for early biological risk reduction through localized intervention, avoiding systemic exposure. The company's initial development programs address gingival inflammation linked to Porphyromonas gingivalis and antimicrobial resistance contexts, including Staphylococcus aureus (MRSA). NARANHAY's technology is applicable across oral care, preventive health, hygiene, and medical device-adjacent use cases, serving both consumer and clinical pathways within the Health Tech & Life Sciences sector.
Company Intelligence Q&A
- What is NARANHAY's primary focus?
- NARANHAY is an advanced antimicrobial biotechnology company developing proprietary, localized formulations to target pathogenic biofilms and microbial drivers of chronic inflammation.
- Who are the founders of NARANHAY?
- NARANHAY was founded by Dr. Aaron Mazin, Maxim Mikhaylov, Adv. Simeon Saharov, and Dr. Yehoshua Maor.
- What specific health issues does NARANHAY's technology address?
- NARANHAY's initial development programs focus on gingival inflammation associated with Porphyromonas gingivalis and antimicrobial resistance contexts, including Staphylococcus aureus (MRSA).
- In which sectors does NARANHAY operate?
- NARANHAY operates within the Health Tech & Life Sciences sector, with applications across oral care, preventive health, hygiene, and medical device-adjacent use cases.
- What is NARANHAY's current product development stage?
- NARANHAY's products are currently in the R&D stage, focusing on developing proprietary antimicrobial solutions.